M&A Deal Summary |
|
|---|---|
| Date | 2019-07-23 |
| Target | Destiny Biosciences Global |
| Sector | Life Science |
| Buyer(s) | Therapix Biosciences |
| Deal Type | Merger |
| Deal Value | 48M USD |
SEARCH BY
Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of Senior Executives and Scientists. Its focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on repurposing an FDA-approved cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Merger M&A Deals | 1 of 1 |
| State: Alberta M&A | 1 of 1 |
| Country: Canada M&A | 1 of 1 |
| Year: 2019 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-10-21 |
Dekel Pharmaceuticals
Ramat Gan, Israel Dekel Pharmaceuticals Ltd. is a privately-held company engaged in the research and development of drug therapies based on synthetic cannabinoid substances. |
Buy | - |
